- Chief Executive Colin Keating to present in London at PSYCH Symposium and to be interviewed by BBC News this week
- MindBio reports on the success of Plant Medicine Week in Malta and provides video recording of keynote presentation
- Co-founder Justin Hanka conducting non-deal broker roadshow in Canada and appearing on investor panel and delivering keynote presentation in Washington DC in May.
- MindBio wins prestigious communications award
- Recent completion of Phase 1 Clinical Trials with data analysis now underway ahead of preparations for Phase 2 Clinical Trials in patients with Major Depressive Disorder and late-stage cancer patients
Vancouver, British Columbia – TheNewswire - May 11, 2022 – Blackhawk Growth Corp. (CSE:BLR) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to report an acceleration and expansion of global market communication activities by its wholly-owned subsidiary, MindBio Therapeutics Pty. Ltd. (“MindBio”).
MindBio was recently a headline sponsor at Plant Medicine Week in Malta. MindBio Co-Founder Justin Hanka delivered a keynote presentation to attendees outlining MindBio’s ambition to change the course of mental health treatments and prevent suicide. He explains MindBio’s investment thesis in the sector pioneering novel psychedelic microdosing treatments through it’s world first clinical trials. You can view the newly released video of Justin Hanka’s keynote presentation on YouTube here.
This week MindBio is in London at the PSYCH Symposium and MindBio Chief Executive Officer, Colin Keating will be presenting with other industry leaders on a panel discussing the future of psychedelic medicines and will be interviewed by BBC News.
Next week, MindBio Co-Founder Justin Hanka is conducting a non-deal roadshow with brokers and investors in Vancouver and Toronto. After that, he will head to Washington DC (USA) for the Psychedelic Therapeutics and Drug Development Conference. Mr. Hanka is participating in an investor panel with leading industry experts and is also delivering a keynote presentation on MindBio’s world first clinical trials microdosing LSD.
MindBio remains the only organization in the world to have successfully received government approvals to administer LSD (lysergic acid diethylamide) to patients in clinical trials who take the drug out in the community and at home in the same way they would take any other medication. The Company recently announced the completion of Phase 1 clinical trials.
MindBio is accelerating its global communications strategy to advance the company’s narrative in mental health treatments and recently was recognised with a Horizon Active Gold Marketing Award for an psychedelics explainer video alongside an impressive line-up of household names, including Porsche.
“MindBio is leading the way in psychedelic microdosing clinical trials.” said Frederick Pels, CEO of Blackhawk. “With the recent successful completion of MindBio’s Phase 1 clinical trial, the MindBio team is now accelerating its global communications strategy as it unravels the data from clinical trials and prepares for Phase 2 Clinical Trials and progressing towards commercialization,”
About Blackhawk Growth
Blackhawk is an investment holding company looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, MindBio Therapeutics, Digital Mind Therapeutics, Blum Distributors as well as an equity position in Gaia Grow Corp. (CSE:GAIA).
The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A
Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Company within the meaning of applicable securities laws, including with respect to transaction and future operations of MindBio Therapeutics Pty Ltd. The Company provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Company’s public filings under the Company’s SEDAR profile at www.sedar.com. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.